Loading...
The clinical course of indolent non-Hodgkin lymphoma (NHL) is characterized by alternating therapeutic response and recurrence after chemo- and immunotherapy. Nearly all patients ultimately succumb to progressive and refractory disease, cumulative therapeutic toxicities, or transformation to aggressive histology. The role and timing of high-dose therapy and autologous or allogeneic stem-cell transplantation (SCT) for indolent NHL has sparked considerable debate, although a subset of patients experience durable remission with this approach.
In a retrospective analysis, investigators examined data from 62 patients with relapsed, refractory, or transformed indolent NHL who underwent nonmyeloablative SCT from related or unrelated donors at 10 U.…